Patents by Inventor Hans-Willi Krell

Hans-Willi Krell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HER3 antibodies and uses thereof
    Patent number: 10196456
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 5, 2019
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20170174784
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 22, 2017
    Applicant: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID
    Publication number: 20170107550
    Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.
    Type: Application
    Filed: June 21, 2016
    Publication date: April 20, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans-Willi Krell, Alexander Lifke, Valeria Lifke, Kairat Madin, Christian Weilke
  • Anti-HER3 antibodies and uses thereof
    Patent number: 9611331
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Method for obtaining immunoglobulin encoding nucleic acid
    Patent number: 9399670
    Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: —performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: July 26, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hans-Willi Krell, Alexander Lifke, Valeria Lifke, Kairat Madin, Christian Weilke
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 9290567
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • METHOD FOR OBTAINING FAB FRAGMENTS FROM SINGLE ANTIBODY PRODUCING CELLS BY MULTIPLEXED CPR IN COMBINATION WITH TaqMan PROBES
    Publication number: 20150024434
    Abstract: Herein is reported a method for a multiplex one tube real-time reverse-transcriptase gene-specific polymerase chain reaction for the amplification and quantification of cognate IgG heavy and light chains encoding nucleic acids (human IgG isotype) from a single cell.
    Type: Application
    Filed: September 20, 2012
    Publication date: January 22, 2015
    Inventors: Hans-Willi Krell, Alexander Lifke, Valeria Lifke, Kairat Madin, Christian Weilke
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377272
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377273
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Antibodies against CDCP1 for the treatment of cancer
    Patent number: 8883159
    Abstract: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Birgit Bossenmaier, Georg Fertig, Hans-Willi Krell, Reiner Lammers, Alexander Lifke, Gerhard Niederfellner
  • Anti-HER3 antibodies and uses thereof
    Patent number: 8859737
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 14, 2014
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 8609097
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: December 17, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
  • USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES
    Publication number: 20130310541
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 6, 2013
    Publication date: November 21, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF
    Publication number: 20120258112
    Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Inventors: Hendrik Knoetgen, Hans-Willi Krell, Sandra Miller, Jens Niewoehner, Dirk Ponsel, Engin Toksoez
  • Antibodies against human CCN1 and uses thereof
    Patent number: 8207307
    Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: June 26, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hendrik Knoetgen, Hans-Willi Krell, Sandra Miller, Jens Niewoehner, Dirk Ponsel, Engin Toksoez
  • Antibodies specifically binding to human TSLPR and methods of use
    Publication number: 20120020988
    Abstract: An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 26, 2012
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: JOHANNES AUER, MARIA FUENTES, GUY GEORGES, HUBERT KETTENBERGER, HANS-WILLI KRELL, JENS NIEWOEHNER, GEORG TIEFENTHALER
  • METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID
    Publication number: 20110306094
    Abstract: The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps:—performing a first polymerase chain reaction with three to six 5?-primer and one 3?-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5?-primer and one 3?-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 15, 2011
    Inventors: Hans-Willi Krell, Alexander Lifke, Valeria Lifke, Kairat Madin, Christian Weilke
  • Pharmaceutical compositions of pyrimidine-2,4,6-triones
    Patent number: 8044035
    Abstract: A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: October 25, 2011
    Assignee: Universite De Liege
    Inventors: Pierre Bartsch, Didier Cataldo, Richard Endele, Brigitte Evrard, Jean-Michel Foidart, Hans-Willi Krell, Gerd Zimmermann
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20110171222
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 17, 2010
    Publication date: July 14, 2011
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Antibodies Against CDCP1 for the Treatment of Cancer
    Publication number: 20110070246
    Abstract: The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 24, 2011
    Inventors: Birgit Bossenmaier, Georg Fertig, Hans-Willi Krell, Reiner Lammers, Alexander Lifke, Gerhard Niederfellner